查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2080398

抗肥胖藥物市場：依產品類型、劑型、給藥途徑及最終用戶分類－2026-2032年全球市場預測

Anti-Obesity Drugs Market by Product Type, Dosage Form, Route Of Administration, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，抗肥胖藥物市場將成長至 225.9 億美元，複合年成長率為 12.32%。

主要市場統計數據
基準年 2025 100.1億美元
預計年份：2026年 112.1億美元
預測年份：2032年 225.9億美元
複合年成長率 (%) 12.32%

抗肥胖藥物正從小眾的體重管理藥物類別轉變為慢性心血管代謝疾病治療的核心組成部分。這種轉變源自於公共衛生需求。世界衛生組織（世衛組織）的數據顯示，到2022年，全球將有超過10億人患有肥胖症，而成人肥胖率自1990年以來已加倍以上。

臨床證據也正在改變市場認知。 GLP-1受體促效劑和雙重腸促胰島素療法在減重優於傳統藥物療法，而2.4毫克Semaglutide已被證實可降低有心血管疾病史的超重或肥胖成年人的心血管風險。隨著肥胖症日益被視為一種慢性復發性疾病，抗肥胖藥物對製藥公司、保險公司、醫療保健系統和數位醫療服務提供者而言正變得具有重要的戰略意義。

抗肥胖藥物領域的變革性變化

抗肥胖藥物的格局正受到三大因素的共同影響：臨床療效的提高、醫學界對肥胖症認知的增強以及對長期心血管代謝風險管理需求的日益成長。最新的腸促胰素療法重新定義了患者和臨床醫生的預期。Semaglutide和替澤帕肽的領先臨床試驗表明，在監督治療下，平均減重率可達兩位數。

人工智慧對抗肥胖藥物的累積影響

人工智慧 (AI) 在抗肥胖藥物的整個生命週期中都發揮著重要作用。在藥物發現階段，AI 驅動的建模可輔助標靶辨識、胜肽段最佳化、製劑篩檢和脫靶效應預測。在開發階段，機器學習可透過識別合格的患者、模擬脫落風險和支持自適應證據產生策略來提高臨床試驗的可行性。

關於抗肥胖藥物的關鍵區域見解

由於北美肥胖症盛行率高、GLP-1療法應用較早、專科醫生網路完善以及美國食品藥物管理局（FDA）積極批准，北美仍然是抗肥胖藥物的主要市場。根據美國疾病管制與預防中心（CDC）報告，近期全國調查顯示，美國成年人肥胖症盛行率仍高於40%，這推動了對實證肥胖藥物治療的需求成長。在歐洲，由於歐洲藥品管理局（EMA）的監管准入、國家醫療技術評估以及臨床上對肥胖症作為一種慢性疾病的認知不斷提高，市場正在擴張。然而，各國的報銷率差異顯著，通常受到合併症閾值、治療時間和預算影響評估的影響。

關於抗肥胖藥物的關鍵區域見解

在東協，抗肥胖藥物的研發受到收入水平差異、私人醫療保健的擴張以及都市區肥胖相關糖尿病發病率上升等因素的影響，導致已開發地區和資源匱乏地區在藥物獲取方面存在顯著差距。海灣合作理事會（GCC）是重點關注區域，因為肥胖和糖尿病是重要的公共衛生問題，政府主導的醫療現代化正在支持專科融合、慢性病篩檢、數位醫療的引入以及更廣泛的叢集代謝疾病診療的整合。

主要國家抗肥胖藥物的發展趨勢

美國是抗肥胖藥物市場最具影響力的國家，這得益於其高肥胖率、FDA批准、雇主需求、專家積極研發以及強大的專業分銷網路。同時，在加拿大，透過公共和私人保險公司的審查，循證藥物的可近性正在擴大。在墨西哥和巴西，肥胖和糖尿病的負擔日益加重，對藥物的需求不斷成長，但經濟負擔、保險制度設計、醫生資源以及醫療保健系統的碎片化等因素都影響著藥物的可及性。

為行業領導者提供的實用建議

行業領導者應優先考慮能夠將永續的臨床差異化、真實世界數據、減重和心臟代謝結果、生活品質、用藥依從性和醫療資源利用率等因素與支付方價值提案起來。企業應投資於生產韌性、醫療設備產能、低溫運輸規劃、品質保證和需求預測，以降低高需求市場供應中斷的風險。

抗肥胖藥物的分析調查方法

本執行摘要基於系統的二手研究調查方法，使用了檢驗的公共衛生、監管和臨床資訊來源。輸入資料包括世界衛生組織 (WHO) 的肥胖統計資料、來自國家公共衛生機構（例如美國疾病管制與預防中心 (CDC)、美國食品藥物管理局 (FDA) 和歐洲藥品管理局 (EMA)）的監管資訊、同行評審的臨床實驗室檢測結果、臨床實踐指南以及來自經濟合作暨發展組織 (OECD) 和國家保險報銷機構的醫療保健系統證據。

關於抗肥胖藥物市場的結論

抗肥胖藥物市場正進入一個新階段，其特點是臨床期望高、目標人口不斷擴大以及與心血管代謝護理的融合更加緊密。腸促胰素療法正在改變藥物減重的標準，而心血管結局的證據也進一步強化了肥胖治療作為預防醫學手段的有效性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：抗肥胖藥物市場：依產品類型分類

  • GLP-1促效劑
  • 納曲酮安非他酮
  • 奧利司他
  • 托吡拉芬特明
  • SGLT2抑制劑

第8章：抗肥胖藥物市場：以劑型分類

  • 膠囊
  • 注射藥物
    • 預填充筆
    • 管瓶
  • 藥片

第9章：抗肥胖藥物市場：依給藥途徑分類

  • 注射藥物
    • 自動噴油器
    • 預填充筆
    • 管瓶
  • 鼻內
  • 口服

第10章：抗肥胖藥物市場：依最終用戶分類

  • 診所
  • 居家照護
  • 醫院

第11章：抗肥胖藥物市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章：抗肥胖藥物市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：抗肥胖藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Alvogen Iceland EHF
  • Amgen Inc
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Cipla Ltd.
  • Currax Pharmaceuticals LLC
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F Hoffmann La Roche Ltd
  • Gelesis Holdings Inc.
  • GlaxoSmithKline plc
  • Hanmi Pharmaceutical Co., Ltd.
  • Innovent Biologics Inc
  • Intas Pharmaceuticals Ltd.
  • LG Chem Ltd
  • Merck and Co Inc
  • Novartis AG
  • Novo Nordisk AS
  • Pfizer Inc
  • Rhythm Pharmaceuticals Inc
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
  • Zealand Pharma A/S
  • Zydus Lifesciences Ltd
Product Code: MRR-434CCDA05185

The Anti-Obesity Drugs Market is projected to grow by USD 22.59 billion at a CAGR of 12.32% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.01 billion
Estimated Year [2026] USD 11.21 billion
Forecast Year [2032] USD 22.59 billion
CAGR (%) 12.32%

Anti-obesity drugs are moving from a niche weight-management category to a core pillar of chronic cardiometabolic care. The shift is grounded in public-health need: the World Health Organization reported that more than 1 billion people were living with obesity in 2022, and adult obesity has more than doubled since 1990.

Clinical evidence has also changed the market narrative. GLP-1 receptor agonists and dual incretin therapies have demonstrated weight-loss outcomes that exceed older pharmacologic options, while semaglutide 2.4 mg has shown cardiovascular risk-reduction benefits in adults with established cardiovascular disease and overweight or obesity. As obesity is increasingly treated as a chronic, relapsing disease, anti-obesity medications are gaining strategic relevance for pharmaceutical companies, payers, health systems, and digital care providers.

Transformative Shifts in the Anti-Obesity Drugs Landscape

The anti-obesity drugs landscape is being reshaped by three converging forces: stronger clinical efficacy, broader medical recognition of obesity, and rising demand for long-term cardiometabolic risk management. Modern incretin-based therapies have reset patient and clinician expectations, with pivotal trials for semaglutide and tirzepatide showing double-digit average weight reduction under supervised treatment.

This transformation is also creating operational pressure. Demand has tested manufacturing capacity for injectable therapies, while payers are evaluating coverage through clinical value, durability of response, comorbidity reduction, safety profile, and total cost of care. Telehealth, employer-sponsored obesity programs, and integrated diabetes-obesity clinics are accelerating patient access, but they also raise expectations for appropriate prescribing, adherence monitoring, lifestyle support, and long-term safety surveillance.

Cumulative Impact of Artificial Intelligence on Anti-Obesity Drugs

Artificial intelligence is compounding value across the anti-obesity drugs lifecycle. In discovery, AI-enabled modeling supports target identification, peptide optimization, formulation screening, and prediction of off-target effects. In development, machine learning can improve trial feasibility by identifying eligible patients, modeling dropout risk, and supporting adaptive evidence-generation strategies.

The cumulative impact is greatest when AI connects clinical, real-world, and operational data. Predictive analytics can support dose optimization, adverse-event detection, adherence interventions, patient stratification, and supply forecasting for high-demand therapies. For industry leaders, the priority is not simply AI adoption, but validated, auditable AI governance that aligns with regulatory expectations, privacy laws, and clinical accountability in obesity care.

Key Regional Insights for Anti-Obesity Drugs

North America remains a leading anti-obesity drugs region due to high obesity prevalence, early adoption of GLP-1 based therapies, established specialist networks, and active FDA-regulated approvals. The CDC reported that adult obesity prevalence in the United States remained above 40% in recent national survey periods, reinforcing demand for evidence-based obesity pharmacotherapy. Europe is advancing through EMA-regulated access, national health technology assessments, and growing clinical recognition of obesity as a chronic disease, although reimbursement remains uneven across countries and often depends on comorbidity thresholds, treatment duration rules, and budget-impact reviews.

Asia-Pacific is positioned for rapid growth as China, India, Japan, South Korea, and Australia confront rising obesity, type 2 diabetes, and cardiovascular risk linked to urbanization, dietary change, and aging populations. Latin America, led by Brazil and Mexico, shows strong medical need as obesity and diabetes burdens increase, but affordability, insurance coverage, and fragmented care pathways continue to shape access. The Middle East, particularly Gulf markets, has high obesity and diabetes prevalence that supports demand for advanced anti-obesity medications, specialist endocrinology care, and government-led chronic disease programs. Africa presents long-term potential, shaped by urbanization, dual malnutrition burdens, uneven diagnostic capacity, and the need for affordable, scalable obesity-care pathways that can be integrated into primary care.

Key Group Insights for Anti-Obesity Drugs

Within ASEAN, anti-obesity drug development is shaped by diverse income levels, expanding private healthcare, and increasing obesity-related diabetes across urban populations, with access differing significantly between advanced health systems and lower-resource settings. The GCC is a high-priority cluster because obesity and diabetes are major public-health priorities, and government-backed healthcare modernization supports specialty prescribing, chronic disease screening, digital health deployment, and broader cardiometabolic care integration.

The European Union provides a harmonized regulatory pathway through the EMA, but pricing and reimbursement remain country specific, requiring evidence packages that address national health technology assessment expectations. BRICS countries combine large patient pools with wide access variation, making localization, affordability, local clinical evidence, and domestic partnerships important for anti-obesity medications. G7 markets anchor innovation, clinical evidence generation, regulatory precedent, and premium reimbursement discussions, especially where obesity is managed alongside diabetes and cardiovascular disease. NATO is not a healthcare trade bloc, but many NATO members overlap with advanced pharmaceutical markets where supply security, cold-chain resilience, pharmacovigilance systems, and regulatory alignment influence anti-obesity drug availability.

Key Country Insights for Anti-Obesity Drugs

The United States is the most influential commercial country for anti-obesity drugs, supported by high obesity prevalence, FDA approvals, employer demand, active specialist prescribing, and strong specialty distribution, while Canada is expanding evidence-based access through public and private payer review. Mexico and Brazil show rising need due to obesity and diabetes burdens, with access shaped by affordability, insurance design, physician availability, and health-system fragmentation.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are guided by national reimbursement and health technology assessment priorities that assess clinical benefit, treatment eligibility, safety, and budget impact, while Russia faces a more complex access and supply environment. China and India offer major long-term patient-volume potential because of large populations, rising metabolic disease prevalence, and expanding healthcare investment, but pricing, local evidence, regulatory pathways, and domestic competition matter. Japan, Australia, and South Korea combine advanced healthcare systems with strong regulatory standards, aging populations, and growing cardiometabolic-care demand, making physician education, reimbursement clarity, and long-term outcomes evidence central to adoption.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize durable clinical differentiation, real-world evidence, and payer-ready value propositions that connect weight loss with cardiometabolic outcomes, quality of life, medication persistence, and healthcare utilization. Companies should invest in manufacturing resilience, device capacity, cold-chain planning, quality assurance, and demand forecasting to reduce supply disruptions in high-demand markets.

Commercial strategies should pair specialist education with responsible patient access models, including obesity screening, contraindication review, nutrition support, physical activity guidance, behavioral care, and long-term adherence programs. AI initiatives should be deployed under clear governance, bias testing, data privacy safeguards, and pharmacovigilance controls. Partnerships with payers, employers, digital health platforms, public-health stakeholders, and local distributors can strengthen access while supporting equitable, medically appropriate obesity treatment.

Research Methodology for Anti-Obesity Drugs Analysis

This executive summary is built on a structured secondary-research methodology using verified public-health, regulatory, and clinical sources. Inputs include World Health Organization obesity statistics, national public-health agencies such as the CDC, regulatory information from the FDA and EMA, peer-reviewed clinical trial publications, clinical practice guidance, and health-system evidence from OECD and national reimbursement bodies.

The analysis triangulates epidemiology, approved therapies, clinical outcomes, access dynamics, reimbursement signals, regional healthcare infrastructure, and supply-chain considerations. Market interpretation emphasizes evidence-backed drivers and restraints, avoiding unsupported projections. Keyword mapping reflects industry terminology used by pharmaceutical executives, investors, healthcare strategists, and policy stakeholders evaluating anti-obesity drugs, GLP-1 therapies, obesity pharmacotherapy, incretin-based treatments, weight management medications, and cardiometabolic disease management.

Conclusion on the Anti-Obesity Drugs Market

The anti-obesity drugs market is entering a new phase defined by high clinical expectations, expanding treatment eligibility, and closer integration with cardiometabolic care. Incretin-based therapies have changed the standard for pharmacologic weight management, while cardiovascular outcomes evidence is strengthening the case for obesity treatment as preventive medicine.

Future leadership will depend on more than efficacy alone. Companies that combine differentiated science, reliable supply, evidence-based reimbursement strategies, responsible AI, and equitable access models will be best positioned. As obesity prevalence continues to rise worldwide, anti-obesity medications are set to remain a strategic priority for healthcare systems, pharmaceutical innovators, and investors focused on long-term chronic disease management.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Anti-Obesity Drugs Market, by Product Type

  • 7.1. Glp-1 Agonists
  • 7.2. Naltrexone Bupropion
  • 7.3. Orlistat
  • 7.4. Phentermine Topiramate
  • 7.5. Sglt2 Inhibitors

8. Anti-Obesity Drugs Market, by Dosage Form

  • 8.1. Capsules
  • 8.2. Injectables
    • 8.2.1. Prefilled Pens
    • 8.2.2. Vials
  • 8.3. Tablets

9. Anti-Obesity Drugs Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Autoinjector
    • 9.1.2. Prefilled Pen
    • 9.1.3. Vial
  • 9.2. Nasal
  • 9.3. Oral

10. Anti-Obesity Drugs Market, by End User

  • 10.1. Clinics
  • 10.2. Homecare Settings
  • 10.3. Hospitals

11. Anti-Obesity Drugs Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Anti-Obesity Drugs Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Anti-Obesity Drugs Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Concentration Analysis, 2025
    • 14.1.1. Concentration Ratio (CR)
    • 14.1.2. Herfindahl Hirschman Index (HHI)
  • 14.2. Recent Developments & Impact Analysis, 2025
  • 14.3. Product Portfolio Analysis, 2025
  • 14.4. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Alvogen Iceland EHF
  • 15.2. Amgen Inc
  • 15.3. AstraZeneca plc
  • 15.4. Bayer AG
  • 15.5. Boehringer Ingelheim International GmbH
  • 15.6. Cipla Ltd.
  • 15.7. Currax Pharmaceuticals LLC
  • 15.8. Dr. Reddy's Laboratories Ltd.
  • 15.9. Eli Lilly and Company
  • 15.10. F Hoffmann La Roche Ltd
  • 15.11. Gelesis Holdings Inc.
  • 15.12. GlaxoSmithKline plc
  • 15.13. Hanmi Pharmaceutical Co., Ltd.
  • 15.14. Innovent Biologics Inc
  • 15.15. Intas Pharmaceuticals Ltd.
  • 15.16. LG Chem Ltd
  • 15.17. Merck and Co Inc
  • 15.18. Novartis AG
  • 15.19. Novo Nordisk A S
  • 15.20. Pfizer Inc
  • 15.21. Rhythm Pharmaceuticals Inc
  • 15.22. Sanofi S.A.
  • 15.23. Sun Pharmaceutical Industries Ltd.
  • 15.24. Takeda Pharmaceutical Company Limited
  • 15.25. Teva Pharmaceutical Industries Ltd
  • 15.26. Zealand Pharma A/S
  • 15.27. Zydus Lifesciences Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-OBESITY DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ANTI-OBESITY DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ANTI-OBESITY DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ANTI-OBESITY DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-OBESITY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL ANTI-OBESITY DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GLP-1 AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GLP-1 AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GLP-1 AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NALTREXONE BUPROPION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NALTREXONE BUPROPION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NALTREXONE BUPROPION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ORLISTAT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ORLISTAT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ORLISTAT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PHENTERMINE TOPIRAMATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PHENTERMINE TOPIRAMATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PHENTERMINE TOPIRAMATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SGLT2 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SGLT2 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SGLT2 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INJECTABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INJECTABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PREFILLED PENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PREFILLED PENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PREFILLED PENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AUTOINJECTOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AUTOINJECTOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AUTOINJECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PREFILLED PEN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PREFILLED PEN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PREFILLED PEN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NASAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NASAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NASAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. GCC ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 115. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 117. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 118. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 120. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. G7 ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 136. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 138. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 139. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 141. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. NATO ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 145. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 146. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 148. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. CANADA ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 160. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 161. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 163. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 165. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 167. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 168. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 170. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 172. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 174. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 175. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 177. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 186. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 188. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 189. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 191. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 195. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 196. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 198. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 202. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 203. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 204. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 205. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. ITALY ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 207. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 209. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 210. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 212. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 214. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 216. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 217. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 219. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. INDIA ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 228. INDIA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. INDIA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 230. INDIA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 231. INDIA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. INDIA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 233. INDIA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. JAPAN ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 235. JAPAN ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. JAPAN ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 237. JAPAN ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 238. JAPAN ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. JAPAN ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 240. JAPAN ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. AUSTRALIA ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. AUSTRALIA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. AUSTRALIA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 244. AUSTRALIA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 245. AUSTRALIA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 246. AUSTRALIA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 247. AUSTRALIA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. SOUTH KOREA ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 249. SOUTH KOREA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. SOUTH KOREA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 251. SOUTH KOREA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 252. SOUTH KOREA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 253. SOUTH KOREA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 254. SOUTH KOREA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)